What is Apimeds Pharmaceuticals US, Inc. (APUS) stock price today?

Apimeds Pharmaceuticals US, Inc. (APUS) currently trades at $1.88 per share. The stock has a market capitalization of $2.36M and a P/E ratio of —x.

Is APUS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Apimeds Pharmaceuticals US, Inc. has a Smart Value Score of 22/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is —.

Is Apimeds Pharmaceuticals US, Inc. financially healthy?

Apimeds Pharmaceuticals US, Inc.'s Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of — places it in the —.

APUS

Apimeds Pharmaceuticals US, Inc.

NYSE MKT: APUS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$1.88

+0.00% today

Updated 2026-04-29

Market cap

$2.36M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.41

Dividend yield

—

52W range

$1 – $4

Volume

0.1M

Market cap

$2.36M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.41

Dividend yield

—

52W range

$1 – $4

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.3

Quality

B+

3.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$—

—

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.06x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-1.75M

Key financials

Revenue Net Income Free Cash Flow

Metric	2021	2022	2023	2024	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-1.03M	$-668666.00	$-777694.00	$-1.39M	$-1.78M
EPS	—	—	—	—	$-0.41
Free cash flow	$-823114.00	$-448167.00	$-627790.00	$-733526.00	$-1.75M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
APUS	$2.36M	22	4.3	3.5	5.0	7.3	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Apimeds Pharmaceuticals US, Inc. trades at $1.88. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.

Frequently asked questions

What is Apimeds Pharmaceuticals US, Inc.'s stock price?

Apimeds Pharmaceuticals US, Inc. (APUS) trades at $1.88.

Is Apimeds Pharmaceuticals US, Inc. overvalued?

Smart Value Score 22/100 (Grade F, Strong Sell).

What is the price target of Apimeds Pharmaceuticals US, Inc. (APUS)?

The analyst target price is $—, representing NaN% downside from the current price of $1.88.

Piotroski F-Score?

2/9 — weak financial health.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNYSE MKT

CurrencyUSD

www.mindwavedao.com

Quick metrics

P/S ratio—

ROE—

Beta—

50D MA$8.67

200D MA$16.73

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

APUS vs LLY →APUS vs JNJ →APUS vs ABBV →Stock screener →